Phase 2 N=17 Limbal Stem Cell Deficiency (LSCD) Treatment With Cultivated Stem Cell (CALEC) Graft
Limbal Stem Cell Deficiency
Primary: Primary Safety Events of Interest — 1; 0; 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=37 The Utility of IVCM to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With DED
Dry Eye Disease
Primary: IVCM for Density of Corneal Immune Dendritiform Cells — 9.47; 28.60 cells/mm^2
Phase 4 N=30 Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers
Dry Eye
Primary: Efficacy of Lifitegrast Ophthalmic Solution 5% in Treating the Symptoms of Dry Eye in Contact Lens Wearers as Measured by Change in Total CLDEQ-8 Score From Baseline to…
Phase 2 N=102 Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)
Keratoconjunctivitis Sicca
Primary: Change From Baseline in Corneal Total Fluorescein Staining Score at for the Study Eye at Week 4 — -1.3; -1.7; -1.3 units on a scale — p=0.6199
N/A N=44 Determination of Cell Population in Solution-Induced Corneal Staining (SICS) and Symptomatic Versus Asymptomatic Lens Wearers
Refractive Error · Dry Eye
Primary: Mean Number of Viable Epithelial Cells Collected Directly From the Ocular Surface After 2 Hours and 4 Hours of Wear, Phase 1 — 15; 20; 18; 22 cells
Phase 2 N=213 LME636 in the Relief of Persistent Ocular Discomfort in Subjects With Severe Dry Eye Disease
Dry Eye
Primary: Mean Change From Baseline in Global Ocular Discomfort Score at Day 71 — -7.9; -3.6 units on a scale
Phase 4 N=50 Corneal and Conjunctival Sensitivity and Staining Study
Myopia · Hyperopia
Primary: Corneal Sensitivity — 26.9; 25.5 percent CO2
N/A N=32 Effects of Cataract Extraction Surgery and Limbal Relaxing Incision on Corneal Sensation and Dry Eye
Dry Eye
Primary: The Percentage of Subjects at Month 3 With Corneal Sensitivity < 50 Millimeters (mm) at Any of the Locations Measured — 13; 13; 21.7; 13 Percentage of Subjects
Phase 2 N=137 Safety and Efficacy Study of Cyclosporine Ophthalmic Emulsion in Post-LASIK Patients
Dry Eye Syndromes
Primary: Percentage of Patients With Clinical Success at Month 6 — 64.3; 58.1 Percentage of Patients
N/A N=400 An Observational Study of Dry Eye Prior to Laser-Assisted in Situ Keratomileusis (LASIK) Therapy
Dry Eye Syndromes
Primary: Percentage of Patients in Each Category of the Dry Eye Workshop Severity (DEWS) Scale — 65.0; 29.0; 4.2; 1.8 Percentage of Patients
Phase 2 N=10 A Study of the KIO-201 (Ocular Bandage Gel) for Improving Persistent Corneal Epithelial Defects
Persistent Corneal Epithelial Defect
Primary: Percentage of Patients Achieving Corneal Healing (<0.5 mm2 Lesion Size) of the Persistent Corneal Epithelial Defect at 4 Weeks — 5 Participants
N/A N=12 Long-term Topical Cyclosporine for Atopic Keratoconjunctivitis
Atopic Keratoconjunctivitis
Primary: Ocular Symptoms and Signs Total Composite Score — 29.1; 4.7 units on a scale — p=0.002
Phase 4 N=94 Effect of Contact Lens Wear on Immune Cell Density and Morphology of the Ocular Surface
Myopia · Refractive Error
Primary: Corneal Epithelial Immune Dendritic Cell Density (Central Cornea) — 46.2; 44.8; 62.3 cells/mm2
Phase 2 N=68 Vision Restoration With a Collagen Crosslinked Boston Keratoprosthesis Unit
Keratolysis
Primary: Time From Surgery to Device Loss or Replacement — 95; 34 median weeks from surgery to removal
Phase 4 N=70 Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection
Corneal Endothelial Dystrophy · Corneal Edema
Primary: Immunologic Rejection — 0 Participants
N/A N=1,274 Impact of Donor Diabetes on DMEK Success and Endothelial Cell Loss
Corneal Endothelial Decompensation · Fuchs' Endothelial Dystrophy
Primary: Graft Failure — 32; 15 eyes
N/A N=135 Performance and Safety Assessment of T4020 in Managing Corneal Epithelial Defect Following Epi-off Accelerated Crosslinking
Keratoconus
Primary: Number of Participants With Complete Healing of Corneal Epithelial Defect at Day 3 — 20; 25 Participants
Phase 2 N=131 Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects
Neurotrophic Keratitis
Primary: Efficacy as Assessed by Complete Corneal Healing — 21; 16 Participants
Phase 4 N=13 Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients
Allergic Conjunctivitis
Primary: Patient-Assessed Ocular Itching — 2.2; 2.2; 0.5; 0.5 units on a scale
Phase 2 N=20 Bandage Lenses in Treating Patients With Ocular Graft-Versus-Host Disease
Graft Versus Host Disease · Ophthalmologic Complications
Primary: Change in Patient-reported Symptoms Measured by the 8-point Lee Eye Subscale — 75.4; 63.2; 61.8; 56.3 units on a scale — p=0.01
Phase 3 N=130 Corneal Collagen Cross-Linking for Ectasia (CXL)
Ectasia
Primary: Mean Change From Baseline in Maximum Keratometry (Kmax) — -0.5; 0.5 diopters
N/A N=24 Open Eye Corneal Swelling With Daily Disposable Contact Lenses and no Lens Wear
Corneal Swelling
Primary: Percentage Change From Baseline of Corneal Swelling 8 Hours Post Fit — 0.07; -0.02; 0.14; -0.06 percentage of change from baseline
Phase 3 N=147 Cross-linking for Corneal Ulcers Treatment Trial
Corneal Ulcer · Infectious Keratitis · Bacterial Ulcer
Primary: Microbiological Cure on Repeat Culture — 5; 5; 17; 14 Participants
Phase 3 N=357 Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis
Conjunctivitis · Keratitis · Blepharitis
Primary: Signs and Symptoms Composite Score - Change From Baseline to Day 15 - PP Population — -11.63; -12.41 Scores on a scale
Phase 2 N=1 Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis
Chemical Injuries · Unspecified Complication of Corneal Transplant · Autoimmune Diseases
Primary: Changes in Corneal Thickness at 1 Millimeter — 730; 760; 700; 720 micrometer
Phase 1 N=1 Intravitreal Mesenchymal Stem Cell Transplantation in Advanced Glaucoma.
Retinal Degeneration · Primary Open-angle Glaucoma
Primary: Type and Severity of Adverse Effects (AE) and Adverse Reactions (AR) — 1 Participants
N/A N=1,090 Cornea Donor Study
Corneal Disease · Fuch's Dystrophy · Pseudophakic Corneal Edema
Primary: Graft Failure — 142; 82 participants
Phase 1 N=165 Topical Autologous Serum Application for the Treatment of Corneal Epithelium Defect After Ocular Surgeries
Corneal Epithelial Defect · Diabetic Retinopathy · Penetrating Keratoplasty
Primary: Patients With Corneal Epithelial Healing Time Within 14 Days — 78; 73 participants
N/A N=5 Safety and Effectiveness of Collagen-phosphorylcholine Bioengineered Cornea in Patients Requiring Lamellar Keratoplasty
Corneal Ulcer · Leukoma
Primary: Incidence of Treatment-Emergent Adverse Events — 0 events
N/A N=205 Longitudinal Evaluation of Silicone Hydrogel (LASH) Study
Corneal Infiltrates
Primary: Cumulative Incidence of Corneal Inflammatory Events — 26.7 annual incidence per 100 subjects